MX2007013584A - Anticuerpos de isoforma de cspcna y sus usos. - Google Patents
Anticuerpos de isoforma de cspcna y sus usos.Info
- Publication number
- MX2007013584A MX2007013584A MX2007013584A MX2007013584A MX2007013584A MX 2007013584 A MX2007013584 A MX 2007013584A MX 2007013584 A MX2007013584 A MX 2007013584A MX 2007013584 A MX2007013584 A MX 2007013584A MX 2007013584 A MX2007013584 A MX 2007013584A
- Authority
- MX
- Mexico
- Prior art keywords
- binding antibodies
- cancer specific
- isoform binding
- pcna isoform
- specific pcna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67527505P | 2005-04-27 | 2005-04-27 | |
| US68961405P | 2005-06-09 | 2005-06-09 | |
| PCT/US2006/016096 WO2006116631A2 (en) | 2005-04-27 | 2006-04-27 | Cancer specific pcna isoform binding antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007013584A true MX2007013584A (es) | 2008-04-22 |
Family
ID=37215524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007013584A MX2007013584A (es) | 2005-04-27 | 2006-04-27 | Anticuerpos de isoforma de cspcna y sus usos. |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20080206140A1 (enExample) |
| EP (1) | EP1874823B1 (enExample) |
| JP (1) | JP2008539271A (enExample) |
| AU (1) | AU2006239318A1 (enExample) |
| CA (1) | CA2605745A1 (enExample) |
| EA (1) | EA200702361A1 (enExample) |
| MX (1) | MX2007013584A (enExample) |
| WO (1) | WO2006116631A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7294471B2 (en) * | 2002-02-27 | 2007-11-13 | Cskeys, Llc | Method for purifying cancer-specific proliferating cell nuclear antigen |
| EA200801847A1 (ru) * | 2006-02-17 | 2009-02-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ |
| CA3023068C (en) | 2008-07-24 | 2022-06-21 | Indiana University Research And Technology Corporation | Cancer peptide therapeutics |
| WO2011044374A1 (en) * | 2009-10-07 | 2011-04-14 | Indiana University Research And Technology Corporation | Capcna peptide therapeutics for cancer |
| US8455200B2 (en) | 2009-10-15 | 2013-06-04 | Traxxsson, Llc | Measurement of PKA for cancer detection |
| WO2012173677A2 (en) * | 2011-03-23 | 2012-12-20 | Indiana University Research And Technology Corporation | Anticancer therapeutic agents |
| PL3122766T3 (pl) | 2014-03-24 | 2021-09-13 | IMMCO Diagnostics, Inc. | Ulepszone wykrywanie i diagnostyka przeciwciał przeciwjądrowych dla układowych i nieukładowych zaburzeń autoimmunologicznych |
| US10420840B2 (en) | 2015-04-10 | 2019-09-24 | Rll, Llc | Anticancer therapeutic agents |
| CA3047230A1 (en) * | 2016-12-15 | 2018-06-21 | The National Institute for Biotechnology in the Negev Ltd. | Anti-pcna monoclonal antibodies and use thereof |
| MA52889A (fr) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2305625A1 (en) * | 1997-09-29 | 1999-04-08 | University Of Maryland, Baltimore | Altered dna synthesome components as biomarkers for malignancy |
| US7294471B2 (en) * | 2002-02-27 | 2007-11-13 | Cskeys, Llc | Method for purifying cancer-specific proliferating cell nuclear antigen |
| DE602004015064D1 (de) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
| US8574848B2 (en) * | 2006-09-13 | 2013-11-05 | Oncimmune Ltd. | Immunoassay methods |
-
2006
- 2006-04-27 EP EP06751685.6A patent/EP1874823B1/en not_active Expired - Lifetime
- 2006-04-27 US US11/912,704 patent/US20080206140A1/en not_active Abandoned
- 2006-04-27 CA CA002605745A patent/CA2605745A1/en not_active Abandoned
- 2006-04-27 JP JP2008509143A patent/JP2008539271A/ja active Pending
- 2006-04-27 AU AU2006239318A patent/AU2006239318A1/en not_active Abandoned
- 2006-04-27 EA EA200702361A patent/EA200702361A1/ru unknown
- 2006-04-27 MX MX2007013584A patent/MX2007013584A/es not_active Application Discontinuation
- 2006-04-27 WO PCT/US2006/016096 patent/WO2006116631A2/en not_active Ceased
-
2012
- 2012-05-22 US US13/477,419 patent/US9006396B2/en not_active Expired - Lifetime
-
2015
- 2015-03-12 US US14/645,498 patent/US20150259407A1/en not_active Abandoned
-
2018
- 2018-03-05 US US15/911,870 patent/US20180362626A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1874823A2 (en) | 2008-01-09 |
| WO2006116631A3 (en) | 2007-03-22 |
| US20180362626A1 (en) | 2018-12-20 |
| BRPI0607676A2 (pt) | 2009-09-22 |
| CA2605745A1 (en) | 2006-11-02 |
| US20120244076A1 (en) | 2012-09-27 |
| WO2006116631A2 (en) | 2006-11-02 |
| US20150259407A1 (en) | 2015-09-17 |
| EA200702361A1 (ru) | 2008-04-28 |
| US20080206140A1 (en) | 2008-08-28 |
| US9006396B2 (en) | 2015-04-14 |
| JP2008539271A (ja) | 2008-11-13 |
| EP1874823B1 (en) | 2016-01-13 |
| HK1110338A1 (zh) | 2008-07-11 |
| AU2006239318A1 (en) | 2006-11-02 |
| AU2006239318A8 (en) | 2006-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
| NZ598194A (en) | Anti-cmet antibody and its use for the detection and the diagnosis of cancer | |
| CL2007001624A1 (es) | Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular. | |
| EA200702361A1 (ru) | АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ | |
| CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
| BR112013010213A2 (pt) | anticorpos que unem ligantes solúveis de receptores de célula t | |
| IN2009KN02404A (enExample) | ||
| CR20110559A (es) | Anticuerpos específicos para cadherina-17 | |
| EA201270654A1 (ru) | Моноклональные антитела, связывающие b7h6, и их применение | |
| MX2010003581A (es) | Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos. | |
| CO6680656A2 (es) | Anticuerpos para metaloproteinasa -9 de matriz | |
| MX377297B (es) | Anticuerpos tem8 y su uso. | |
| AR076655A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| CU23809A3 (es) | Anticuerpo específico prlr | |
| BR112012031071A2 (pt) | 8-proteínas de ligação à il-1 | |
| CL2012002428A1 (es) | Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende. | |
| CY1113087T1 (el) | Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4 | |
| ECSP088733A (es) | Anticuerpos anti-5t4 y usos de los mismos | |
| EP3587439A3 (en) | Improved quantification of vaccine compositions | |
| CU20120095A7 (es) | Antagonistas de pcsk9 | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
| MX380526B (es) | Desarrollo y uso de sondas fluorescentes de bilirrubina sin enlazar | |
| BR112012019475A2 (pt) | "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |